C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Prior treatment

• Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) not resolved within 72 hours prior to study enrollment.
• Prior treatment with anti-CD47 and/or anti-SIRPα therapy and/or prior glofitamab or anti-CD20xCD3 containing regimen.

Other illness

• Known or suspected primary or secondary CNS lymphoma or meningeal involvement; history of multifocal leukoencephalopathy; history of CNS disease.
• Significant cardiac/cardiovascular/thromboembolic disease.

Other

• High-grade B-Cell lymphoma NOS or High-grade B-Cell lymphoma with MYC and BCL2 rearrangements.

• Adults with histologically confirmed DLBCL and relapsed or refractory disease
• Participant is not a candidate or unwilling to undergo high dose chemotherapy and subsequent autologous stem cell transplant or unable to receive approved chimeric antigen receptor T-cell therapy (CAR-T).
• Measurable disease: at least 1 site of measurable PET-avid disease per Lugano 2014 classification.
• Prior treatment must include at least 2 lines of systemic therapy (for Phase 2: at least 2 but no more than 4 prior lines of systemic therapy). Prior therapy must include an anti-CD20 containing regimen.
• Adequate hematologic, hepatic and renal function.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤2.